Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.06.02.21258242: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: COVAT study is an ongoing, pan-India, cross-sectional study that was approved by the ethical committee of Thakershy Charitable Trust, Ahmedabad, Gujarat, India.
Consent: Written informed consent were taken from all the participants who participated in this study, voluntarily.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The IgG antibodies to SARS- CoV-2 directed against the spike protein (S-antigen, both S1 and S2 protein) were assayed with LIASON® S1/S2 quantitative antibody detection kit (DiaSorin Saluggia, Italy) using indirect chemiluminescence immunoassay (CLIA). IgGsug…SciScore for 10.1101/2021.06.02.21258242: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: COVAT study is an ongoing, pan-India, cross-sectional study that was approved by the ethical committee of Thakershy Charitable Trust, Ahmedabad, Gujarat, India.
Consent: Written informed consent were taken from all the participants who participated in this study, voluntarily.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources The IgG antibodies to SARS- CoV-2 directed against the spike protein (S-antigen, both S1 and S2 protein) were assayed with LIASON® S1/S2 quantitative antibody detection kit (DiaSorin Saluggia, Italy) using indirect chemiluminescence immunoassay (CLIA). IgGsuggested: NoneMoreover, multiple logistic regression analysis was also conducted to find out whether any independent factors were associated with a blunted response to vaccine in anti-spike antibody generation following first dose of vaccination. anti-spikesuggested: NoneSoftware and Algorithms Sentences Resources ) Software Version 22.0 for windows, SPSS Inc., Chicago, IL, USA, with Microsoft Word and Excel being used to generate graphs and tables. SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However, we also acknowledge several limitations. Firstly, in the present study, we have used a convenience sampling amounting to selection bias. A community-based study in a larger population with multi-stage sampling would be an ideal sampling method. Secondly, we used a binary logistic regression (to identify the predictors of non-response to vaccines) which primarily assumes linearity between the explanatory variable and the outcome variable, hence this model may miss out any predictor variable which may have non-linear relationship with the outcome variable. Thirdly, we have measured only anti-spike binding antibody and could not assess NAb and cell-mediated immune response such as Th-1 and Th-2 dependent antibody or cytokines (primarily due to the lack of standardized commercial labs in India). Fourth, we could not measure the baseline anti-spike antibody titre prior to the vaccination, because of logistic issue due to lockdown. Finally, two value of short-term anti-spike antibody as evaluated in this report may not necessarily predict the efficacy of vaccine, nor the absence of seropositivity confer failure of vaccine in absence of NAb and T-cell response assessment. In conclusion, this cross-sectional study after the completion of two doses of both vaccines suggests that both vaccines induce seropositivity to anti-spike antigen in 95% of SARS-COV-2 naïve and recovered individuals after 3-weeks. Whether any real difference in inducing immunogenicity exists between two ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
-
SciScore for 10.1101/2021.04.07.21255078: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: COVAT study is an ongoing, pan-India, cross-sectional study that was approved by the ethical committee of Thakershy Charitable Trust, Ahmedabad, Gujrat, India.
Consent: Written informed consent were taken from all the participants who participated in this study, voluntarily. 2.2 Measurements: Clinical data was collected from all eligible participants including age, sex, blood groups, body mass index (BMI), past history of confirmed SARS-CoV-2 infection, presence of comorbidities such as diabetes mellitus (type 1 [T1DM] and type 2 [T2DM]), hypertension (HTN), dyslipidemia, presence of ischemic heart disease (IHD), chronic kidney disease (CKD) and cancer, …SciScore for 10.1101/2021.04.07.21255078: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: COVAT study is an ongoing, pan-India, cross-sectional study that was approved by the ethical committee of Thakershy Charitable Trust, Ahmedabad, Gujrat, India.
Consent: Written informed consent were taken from all the participants who participated in this study, voluntarily. 2.2 Measurements: Clinical data was collected from all eligible participants including age, sex, blood groups, body mass index (BMI), past history of confirmed SARS-CoV-2 infection, presence of comorbidities such as diabetes mellitus (type 1 [T1DM] and type 2 [T2DM]), hypertension (HTN), dyslipidemia, presence of ischemic heart disease (IHD), chronic kidney disease (CKD) and cancer, including its duration and treatment received.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources The IgG antibodies to SARS-CoV-2 directed against the spike protein (S-antigen, both S1 and S2 protein) were assayed with LIASON® S1/S2 quantitative antibody detection kit (DiaSorin Saluggia, Italy) using indirect chemiluminescence immunoassay (CLIA) as per manufacturer’s protocol. IgGsuggested: NoneThe analyzer automatically calculates SARS-CoV-2 S1/S2 IgG antibody concentrations as arbitrary units (AU/mL) and grades the results. S1/S2 IgGsuggested: NoneMoreover, multiple logistic regression analysis was also conducted to find out whether any independent factors were associated with a blunted response to vaccine in anti-spike antibody generation following first dose of vaccination. anti-spikesuggested: NoneSoftware and Algorithms Sentences Resources Entire statistical analysis was carried out with Statistical Package for Social Sciences (SPSS Complex Samples) Software Version 22.0 for windows, SPSS Inc., Chicago, IL, USA, with Microsoft Word and Excel being used to generate graphs and tables. SPSSsuggested: (SPSS, RRID:SCR_002865)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:However, we also acknowledge several limitations. Firstly, an important consideration for a cross-sectional study design lies in the randomly selected sample obtained from the targeted population for which the results would be generalized. However, in the present study, we have used a convenience sampling amounting to selection bias. Moreover, to answer a research question like antibody response rate, a community-based study in a larger population with multi-stage sampling would have be an ideal sampling method. Furthermore, for the outcome like responder rate, we could not use stratification by the age and sex. Secondly, we used a binary logistic regression (to identify the predictors of non-response to vaccines) which primarily assumes linearity between the explanatory variable and the outcome variable, hence this model may miss out any predictor variable which may have non-linear relationship with the outcome variable. Thirdly, we have measured only anti-spike binding antibody and could not assess neutralizing antibody as well as cell-mediated immune response such as Th-1 and Th-2 dependent antibody or cytokines (primarily due to the lack of standardized commercial labs in India). Furthermore, we could not measure the baseline anti-spike antibody titre prior to the vaccination, because of delay in finalizing the logistic of this study. Finally, a single value of short-term anti-spike antibody as reported in this preliminary report may not necessarily predict the efficacy o...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-